Cat. No. | Product name | CAS No. |
DC46690 |
Gap 27
Featured
Gap 27 is a synthetic connexin-mimetic peptide and acts as a gap junction inhibitor. Gap 27 is highly effective in interrupting co-operative cell-cell interactions, such as the synchronous beating of embryonic cardiomyocytes. |
198284-64-9 |
DC46693 |
DAMGO
Featured
DAMGO (DAGO) is a potent and selective μ opioid receptor agonist with ki of 17 nM. |
78123-71-4 |
DC46694 |
OT-82
Featured
OT-82 is a novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitor with average IC50s of 13.03 nM in non-HP cancer cells and 2.89 nM in HP cancer cells, respectively. |
1800487-55-1 |
DC57060 |
Glucocorticoid receptor modulator-1
Featured
A novel Glucocorticoid receptor modulator. |
2452396-89-1 |
DC57061 |
EHP-101 (VCE- 004.8)
Featured
EHP-101 (VCE-004.8) is an orally active, specific PPARγ and CB2 receptor dual agonist. EHP-101 inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. EHP-101 attenuates adipogenesis and prevents diet-induced obesity. EHP-101 (20 mg/kg/day; i.p.; for 3 weeks) induces a significant reduction in body weight gain, total fat mass, adipocyte volume and plasma triglycerides levels in HFD mice. |
1818428-24-8 |
DC57070 |
PY-60
Featured
PY-60 is a novel activator of YAP-dependent gene expression.It targets ANXA2 in the Hippo pathway. PY-60 targets ANXA2 to activate YAP[1]. PY-60, a thiazole-substituted derivative, dose-dependently induces luciferase activity in 293A-TEAD-LUC cells in the presence or absence of serum when cells were plated at high cell density (EC50= 1.5 and 1.6 µM, respectively). PY-60 treatment also dose-dependently promoted the association of YAP and TEAD proteins in cells and induced the nuclear localization of YAP in response to increased cell density. PY-60 robustly increases the levels of YAP-controlled transcripts (that is, ANRKD1, CYR61 and CTGF) in 293A cells and other human cell lines (that is, MCF10A, HEK293T, H69 and HaCaT), but did not augment the levels of YAP itself (YAP1)[1]. PY-60 activates a proproliferative, YAP-dependent transcriptional program in the adult animal capable of remodeling the epidermis through proliferation[1]. PY-60 liberates the ANXA2-YAP complex from the cell membrane and competes for ANXA2 binding of phosphoinositides[1]. PY-60 (10 uM; applied topically to the dorsal skin of wild-type adult C57BL/6 mice over the course of 10 days) promotes a dramatic expansion of keratinocytes and K14-positive precursors, as assessed by hematoxylin and eosin and anti-K14 histological staining at the study end. PY-60 results in an approximate doubling of epidermal thickness, a result derived from an increased number of keratinocytes per unit length of skin[1]. |
2765218-56-0 |
DC57071 |
HB007
Featured
HB007 is a novel small-molecule degraders of the small ubiquitin-related modifier 1 (SUMO1). |
2387821-46-5 |
DC60115 |
Enfuvirtide Acetate
Featured
Enfuvirtide acetate salt is a linear synthetic peptide made of 36 amino acids. It has an acetylated N-terminus and a carboxamide C-terminus. |
914454-00-5 |
DC57073 |
VX-150
Featured
VX-150 (EOS-62073), a NaV1.8 blocker, is currently in a phase II clinical trial for the treatment of patients with acute pain. VX-150 significantly alleviates postoperative pain. |
1793080-72-4 |
DC60116 |
Pimethixene
Featured
Pimethixene or Calmixen is antihistamine and anticholinergic of the thioxanthene chemical class that is often used to treat hyperactivity, anxiety, sleep disorders, and allergy. |
314-03-4 |
DC60117 |
RS-25344 hydrochloride
Featured
RS-25344 HCl is a potent and selective phosphodiesterase (PDE) 4 inhibitor (IC50 values are 0.28, > 100, 160 and 330 nM at PDE4, PDE1, PDE2 and PDE3 respectively). It inhibits eosinophil chemotaxis and increases progressive motility of spermatozoa in vitro. |
152815-28-6 |
DC57076 |
GPR65 agonist (BTB09089)
Featured
GPR65 agonist (BTB09089) is a novel GPR65 agonist. |
245728-44-3 |
DC60118 |
Fezolinetant HCl
Featured
Fezolinetant, also known as ESN-364, is Neurokinin-3 (NK-3) receptor antagonist which has been optimized for use in women’s health, and is being developed for sex-hormone related disorders such as endometriosis, polycystic ovarian syndrome and uterine fibroids. |
929016-98-8 |
DC57080 |
XEN723
Featured
XEN723 is a novel and potent thiazolylimidazolidinone inhibitor of Stearoyl-CoA Desaturase (SCD1) with IC50s of 45 and 524 nM in mouse and HepG2 cell, respectively. |
1072803-08-7 |
DC57081 |
FIDAS-3
Featured
FIDAS-3 is a stilbene derivative and is a potent Wnt inhibitor with an IC50 of 4.9 μM for methionine S-adenosyltransferase 2A (MAT2A). FIDAS-3 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-3 has anticancer activities. |
1266684-01-8 |
DC57083 |
Necrostatin-34
Featured
Necrostatin-34 (Nec-34), a RIPK1 kinase inhibitor, stabilizes RIPK1 kinase in an inactive conformation by occupying a distinct binding pocket in the kinase domain. |
375835-43-1 |
DC57085 |
TAK-653
Featured
TAK 653 (also known as NBI 1065845) is an oral small molecule, positive allosteric modulators of AMPA (AMPA-PAM) receptors |
1358751-06-0 |
DC57090 |
MIPS-521
Featured
MIPS521 is a positive allosteric modulator of the adenosine A1 receptor. |
1146188-19-3 |
DC60119 |
YQ128
Featured
YQ128 is a potent and selective second-generation NLRP3 (NOD-like receptor P3) inflammasome inhibitor with an IC50 of 0.30 ± 0.01 μM. Further studies from in vitro and in vivo models confirmed its selective inhibition on the NLRP3 inflammasome and its brain penetration. Furthermore, pharmacokinetic studies in rats at 20 mg/kg indicated extensive systemic clearance and tissue distribution, leading to a half-life of 6.6 h. |
2454246-18-3 |
DC60120 |
QQN05022(Dot1L-IN-4)
Featured
QQN05022, also known as Dot1L-IN-4 is a potent disruptor of telomeric silencing 1-like protein (DOT1L) inhibitor. This molecule was first reported in ACS Medicinal Chemistry Letters (2019), 10(12), 1655-1660. This product has no formal name at the moment. For the convenience of communication, a temporal code name was therefore proposed according to MedKoo Chemical Nomenclature. |
2565705-02-2 |
DC60121 |
NVP-BHG712 isomer
Featured
NVP-BHG712 isomer is a regioisomer of NVP-BHG712, which shows conserved non-bonded binding to EPHA2 and EPHB4. BHG-712, is a EphB4 kinase inhibitor and BCR-ABL inhibitor. NVP-BHG712 inhibits EphB4 kinase activity in the low nanomolar range in cellular assays showed high selectivity for targeting the EphB4 kinase when profiled against other kinases in biochemical as well as in cell based assays. |
2245892-85-5 |
DC60122 |
SC-10914
Featured
SC10914 is a highly potent PARP inhibitor (PARP1 IC50 = 7.87 nM) with potent anti-proliferative activity against human BRCA deficient tumor cells (MDA-MB-436, BRCA1 deficient, IC50 = 4.03 nM, Capan-1 BRCA2 deficient, IC50 = 11.66 nM) and PTEN deficient tumor cells (HGC-27,PTEN deficient, IC50 = 0.35 μM). SC10914 showed potent anti-tumor activity in BRCA1/2 mutant tumor models and better pharmacokinetics profile has the potential to be selected as the clinical candidate for the treatment of treatment of BRCA1/2 deficient cancers. |
76985-08-5 |